35 Search Results Found

You searched for: "SOUTH AFRICA"
OMS721: Omeros Research Collaboration with University of Cambridge

OMS721: Omeros Research Collaboration with University of Cambridge

Pharma News: an Atypical HUS update from the aHUS Alliance. In its 11 December 2018 press release, the Omeros Corporation announced a new collaboration with a UK university to create the Omeros Center at Cambridge for Complement and Inflammation Research (OC3IR). Focus of the OC3IR will be research into OMS721 and OMS906, but how will it engage other aHUS stakeholders interested in OMS721 clinical trials and atypical HUS advancements in research?

Continue Reading OMS721: Omeros Research Collaboration with University of Cambridge
Breaking Down Barriers in aHUS Clinical Trials

Breaking Down Barriers in aHUS Clinical Trials

Break down in communication flows and fragmented outreach have built barriers for research and clinical trial enrollment regarding advancing new options for those with the rare disease atypical HUS (aHUS, or hemolytic uremic syndrome). The aHUS Alliance looks at current challenges, and potential pathways to explore and engage.

Continue Reading Breaking Down Barriers in aHUS Clinical Trials
aHUS Alliance – Press Kit

aHUS Alliance – Press Kit

  Patients sharing their rare disease journey help bring new levels of understanding to researchers, industry, and the general public.  Whether you’re living with atypical HUS or a member of…

Continue Reading aHUS Alliance – Press Kit